Charm doses first patient with AI-designed menin inhibitor
Charm has begun human trials of an AI-designed menin inhibitor, with the first patient receiving the drug. The news appeared on 7 October.
Who is affected and how
- pharmaceuticals
- AI-designed molecules entering clinical phases are the first real test of how effective AI-driven research is.
- doctor
- For oncologists, menin inhibitors open up a new trial option.
Sources
- Charm Doses First Patient With AI-Designed Menin Inhibitorpeptideandprotein.com · Oct 7, 2026
- Generate Biomedicines doses first patient with AI-designed IL-18 armored CAR T for ovarian cancergenomethods.org · Oct 7, 2026
- Generate's GB-5267: First Patient Dosed in an AI-Designed CAR T Trialnexi.fund · Oct 8, 2026
- Generate Biomedicines doses first patient in AI-designed 'armored' CAR T trial for ovarian cancerallsci.com · Oct 9, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.